Lyell Immunopharma, Inc.

Direct answer

Lyell Immunopharma, Inc. is publicly traded on NASDAQ under the ticker LYEL.

Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with...

Can you invest in Lyell Immunopharma, Inc.?

Yes. Lyell Immunopharma, Inc. is publicly traded on NASDAQ under the ticker LYEL.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Lyell Immunopharma, Inc.

Detailed equity research is provided by MarketSnap.